Cyclo(Gly-Pro)
Cyclo(Gly-Pro) is a cyclic dipeptide. Cyclo(Gly-Pro) exerts analgesic effects through opioid receptor-related pathways and reduces IFN-γ-induced cellular cytokine/chemokine biomarkers. Cyclo(Gly-Pro) inhibits induced nociception in mouse models, reduces carrageenan- and other inducer-induced paw edema and myeloperoxidase in inflamed paws, and increases the number of c-Fos-positive neurons in the midbrain periaqueductal gray. Cyclo(Gly-Pro) can be used in research related to pain and inflammatory diseases.
For research use only. We do not sell to patients.
- CAS No.: 97011-16-0
- Formula: C7H10N2O17O
- Molecular Weight:155.17
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
IC50 & Target
[4]|
IL-13 |
IL-22 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:IFN-γ-induced AD-like human HaCaT keratinocytes
-
Concentration:1, 10, 100 ppm
10 ng/mL (IFN-γ) -
Incubation Time:24 h
-
Result:Reduced expression of inflammatory biomarkers including sIL‑2R, IL‑13, IL‑22, IL‑31, CCL17 and CCL22 in a dose‑response fashion relative to IFN‑γ‑induced AD‑like keratinocytes.
In Vivo
Cyclo(Gly-Pro) (10 μmol/kg; intraperitoneal injection; 1 h before acetic acid injection) produces a long-lasting analgesic effect in the acetic acid-induced writhing model[2].
Cyclo(Gly-Pro) (0.1-10 μmol/kg; intraperitoneal injection; 60 min after administration) produces receptor-dependent analgesic effects in the hot plate test[2].
Cyclo(Gly-Pro) (10 μmol/kg; intraperitoneal injection; single administration; 85 min after administration) increases neuronal c-Fos expression in the PAG[2].
Cyclo(Gly-Pro) (10 μmol/kg; intraperitoneal injection) attenuates carrageenan-induced mechanical hyperalgesia, paw edema, and neutrophil-associated MPO activity, and pretreatment administration also inhibits paw edema induced by PGE2, 5-hydroxytryptamine, and compound 48/80, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss (male, 18-22 g)[2]
-
Dosage:0.1, 1, or 10 μmol/kg
-
Administration:i.p.; 60 min before intraplantar formalin
-
Result:Inhibited the neurogenic phase by 40.6%, 43.1%, and 48.6%.
Inhibited the inflammatory phase by 39.2%, 47.4%, and 54.9%.
-
Animal Model:Swiss (male, 18-22 g)[2]
-
Dosage:10 μmol/kg
-
Administration:i.p.; 1 h before acetic acid; in separate time-course groups, 1, 2, 4, 6, or 10 h before acetic acid
-
Result:Produced antinociception in acetic acid-induced writhing; the effect was detected 1 h after administration, was maximal between 2-4 h, and lasted up to 6 h; no antinociceptive effect remained at 10 h.
-
Animal Model:Swiss (male, 18-22 g)[2]
-
Dosage:0.1, 1, or 10 μmol/kg
-
Administration:i.p.; reaction time measured 60 min after administration; antagonist (15.3 μmol/kg, i.p.) before administration
-
Result:Increased latency response time to 10.22 s, 16.08 s, and 14.40 s.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 97011-16-0
-
Unlabeled CAS 3705-27-9
-
Molecular Weight 155.17
-
Formula C7H10N2O17O
-
Sequence
Cyclo(Gly-Pro)
-
Sequence Shortening
Cyclo(GP)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[2]. Ferro JN, et al. Cyclo-Gly-Pro, a cyclic dipeptide, attenuates nociceptive behaviour and inflammatory response in mice. Clinical and experimental pharmacology & physiology. 2015 Dec;42(12):1287-95. [Content Brief]
[3]. Harford J. Bacterial utilization of cyclo (glycyl-L-prolyl). Experientia. 1978 Jan 1.
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)